Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Withdrawn 1Terminated 1Completed 1Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1Sarcoma 1Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Genitourinary 1Dermatologic 1CNS 1

Conditions

Multiple Myeloma 1

Interventions

Dexamethasone 393Bortezomib 246Lenalidomide 222Cyclophosphamide 184Melphalan 168Calcium Dobesilate 119Peripheral Blood Stem Cell Transplantation 94fludarabine phosphate 89Thalidomide 82Filgrastim 74carfilzomib 70pomalidomide 68Granulocyte Colony-Stimulating Factor 63Busulfan 63Mycophenolic Acid 61daratumumab 58Whole-Body Irradiation 57ixazomib 54fludarabine 52Tacrolimus 52Prednisone 51Cyclosporine 50Antilymphocyte Serum 35dexamethasone acetate 32plerixafor 30Etoposide 30Methotrexate 29Radiotherapy 28dexamethasone 21-phosphate 27Doxorubicin 26

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × AP 1903 reagent × Plasma cell × Clear all
NCT03958656 2021-09-09

T-cells Expressing an Anti-SLAMF7 CAR for Treating Multiple Myeloma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
13 enrolled 15 charts
Plasma cell

Multiple Myeloma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡